Christmas has come early for Rigel Pharmaceuticals, Inc. with US regulators giving the green light to Rezlidhia a couple of months sooner than expected but the US firm is all set to make the acute myeloid leukemia (AML) drug available by the end of the year.
Rigel Ready To Hit The Ground Running After Early AML Drug Approval
Rezlidhia PDUFA Date Was Mid-February
Rezlidhia, which was only recently licensed by Rigal from Novo Nordisk-owned Forma Therapeutics, should challenge the market dominance of Servier's Tibsovo in the IDH-1 inhibitor subset of acute myeloid leukemia patients.
More from New Products
More from Scrip
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.